Orphan drugs: Pricing, reimbursement and patient access

International Journal of Pharmaceutical and Healthcare Marketing

Volumn 5, Issue 4, 2011, Pages 299-317

  Barak, Adam ^a   Shankar Nandi, Jyoti ^b  

^a PPI Limited   (United Kingdom)

^b UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Diseases; Health policy; Market access; Orphan drugs; Pharmaceuticals industry; Pricing; Rare diseases; Reimbursement

Indexed keywords

EID: 84986133005     PISSN: 17506123     EISSN: None     Source Type: Journal    
DOI: 10.1108/17506121111190121     Document Type: Review

References (57)

1. Ariyanchira, S. (2008), “Biomarket trends: orphan drug arena driven by biologics”, Genetic Engineering & Biotechnology News, Vol. 28 No. 1, available at: www.genengnews.com/gen-articles/biomarket-trends-orphan-drug-arena-driven-by-biologics/2318/ (accessed 18 August 2011).
2. Arnon, S.S. (2007), “Creation and development of the public service orphan drug human botulism immune globulin”, Pediatrics, Vol. 119 No. 4, pp. 785–9.
3. Aronson, J.K. (2006), “Rare diseases and orphan drugs”, British Journal of Clinical Pharmacology, Vol. 61 No. 3, pp. 243–5.
4. British National Formulary (2007), BMJ Group & RPS Publishing, London, p. 623.
5. Bruce, F. (2010), “More European HTA collaboration, but no plans for a EuroNICE”, SCRIP, available at: www.scripintelligence.com/policyregulation/More-European-HTA-collaboration-but-no-plans-for-a-EuroNICE-303878 (accessed 18 August 2011).
6. Denis, A., Simoens, S., Fostier, C., Mergaert, L. and Cleemput, I. (2009), “Policies for orphan diseases and orphan drugs: KCE reports”, Belgian Health Care Knowledge Centre, Brussels.
7. DoH (2010), “A new value-based approach to the pricing of branded medicines – a consultation”, available at: www.dh.gov.uk/en/Consultations/Liveconsultations/DH_122760 (accessed 11 January 2011).
8. Drummond, M.F., Wilson, D.A., Kanavos, P., Ubel, P. and Rovira, J. (2007), “Assessing the economic challenges posed by orphan drugs”, International Journal of Technology Assessment in Health Care, Vol. 23 No. 3, pp. 36–42.
9. EC (2004), “Regulation (EC) no 726/2004 of the European parliament and of the council of 31 March 2004: laying down community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicine Agency”, Article 83, European Commission, Brussels.
10. EC (2011), “Rare diseases: the orphan drugs strategy”, available at: http://ec.europa.eu/health/rare_diseases/orphan_drugs/strategy/index_en.htm (accessed 18 August 2011).
11. EMA (n.d.), “Orphan drugs and rare diseases at a glance”, European Medicines Agency, available at: www.ema.europa.eu/pdfs/human/comp/29007207en.pdf (accessed 18 August, 2011).
12. EMA (2008), List of Orphan-designated Authorised Medicines, European Medicines Agency, London.
13. EMA (2009), “European public assessment report (EPAR) on Glivec”, European Medicines Agency, available at www.ema.europa.eu (accessed 18 August 2011).
14. EMA (2010), “European Medicines Agency road map to 2015: the agency's contribution to science, medicines, health (draft for public consultation)”, European Medicines Agency, available at: www.ema.europa.eu (accessed 3 July 2010).
15. EU Rare Diseases Task Force (2008), “Health indicators for rare diseases: state of the art and future directions”, available at: www.eucerd.eu/__PP__4.html (accessed 18 August 2011).
16. EURORDIS (2009), “Comments on the June 2009 council recommendation on a European action in the field of rare diseases”, available at: www.eurordis.org/content/european-action-field-rare-diseases (accessed 18 August 2011).
17. EURORDIS (2010), “Compassionate access to orphan drugs in the USA”, available at: www.eurordis.org/content/compassionate-access-orphan-drugs-us (accessed 18 August 2011).
18. EURORDIS (2011a), “CAVOD initiative”, available at: www.eurordis.org/content/ertc-workshops (accessed 18 August 2011).
19. EURORDIS (2011b), “Encouraging new drug development: laws, incentives and advocacy”, available at: www.eurordis.org/content/promoting-orphan-drug-development (accessed 18 August 2011).
20. EURORDIS (2011c), “Why orphan drugs?”, available at: www.eurordis.org/about-orphan-drugs (accessed 18 August 2011).
21. Ehreth, J. and Williams, D. (2009), “European pharmaceutical pricing and reimbursement conference”, Expert Review of Pharmacoeconmics & Outcomes Research, Vol. 9 No. 1, pp. 37–9.
22. Europa (2008), “EU commission communication on rare diseases”, available at: http://europa.eu/legislation_summaries/public_health/threats_to_health/sp0006_en.htm (accessed 18 August 2011).
23. European Biopharmaceutical Enterprises and The European Association for Bioindustries (2010), “EBE and EuropaBio hail EU orphan medicinal products regulation a success”, available at: www.europabio.org/PRGeneral.htm (accessed 18 August 2011).
24. European Parliament (2000), Regulation (EC) 141/2000 of the European Parliament and the Council of 16 December 1999 on Orphan Medicinal Products, Brussels.
25. Genzyme Corporation (2010), Genzyme Reports Fourth-quarter Revenue, news release, available at: www.businesswire.com/news/genzyme/20100112006676/en/Genzyme-Reports-Fourth-Quarter-Revenue (accessed 18 August 2011).
26. Grabowski, H.G. and Vernon, J. (2000), “The distribution of sales revenues from pharmaceutical innovation”, Pharmacoeconomics, Vol. 18, Supplement, pp. 21–32.
27. Heemstra, H.E., de Vrueh, R.L., van Weely, S., Büller, H.A. and Leufkens, H.G. (2008), “Predictors of orphan drug approval in the European Union”, European Journal of Clinical Pharmacology, Vol. 64 No. 5, pp. 545–52.
28. Hemphill, T.A. (2009), “Extraordinary pricing of orphan drugs: is it a socially responsible strategy for the US pharmaceutical industry?”, Journal of Business Ethics, Vol. 94 No. 2, pp. 225–42.
29. Heuser, S. (2007), “It costs how much?”, The Boston Globe, May 6, available at: www.boston.com/business/specials/bio2007/articles/high_costs (accessed 18 August 2011).
30. Hughes, D.A., Tunnage, B. and Yeo, S.T. (2005), “Drugs for exceptionally rare diseases: do they deserve special status for funding?”, An International Journal of Medicine, Vol. 98 No. 11, pp. 829–36.
31. Hyde, R. and Dobrovolny, D. (2010), “Orphan drug pricing and payer management in the united states: are we approaching the tipping point?”, Agriculture and Horticulture Development Board, Vol. 3 No. 1, pp. 15–23.
32. Joppi, R., Bertele, V. and Garattini, S. (2009), “Orphan drug development is not taking off”, British Journal of Clinical Pharmacology, Vol. 67 No. 5, pp. 494–502.
33. Lagakos, S.W. (2003), “Clinical trials and rare diseases”, The New England Journal of Medicine, Vol. 348, pp. 2455–6.
34. Lavandeira, A. (2002), “Orphan drugs: legal aspects, current situation”, Haemophilia, Vol. 8 No. 3, pp. 194–8.
35. Lipscomb, J., Drummond, M., Fryback, D., Gold, M. and Revicki, D. (2009), “Retaining, and enhancing, the QALY”, Value Health, Vol. 1, Supplement 1, pp. S18-S26.
36. Love, J. and Palmedo, M. (2001), “Cost of human use clinical trials: surprising evidence from US orphan drug act”, available at: www.cptech.org/ip/health/orphan/irsdata9798.html (accessed 18 August 2011).
37. McCabe, C., Claxton, K. and Culyer, A.J. (2008), “The NICE cost-effectiveness threshold: what it is and what that means”, Pharmacoeconomics, Vol. 26 No. 9, pp. 733–44.
38. McCabe, C., Claxton, K. and Tsuchiya, A. (2005), “Orphan drugs and the NHS: should we value rarity?”, British Medical Journal, Vol. 331 No. 7523, pp. 1016–9.
39. McCabe, C., Tsuchiya, A., Claxton, K. and Raftery, J. (2007), “Assessing the economic challenges posed by orphan drugs: a comment on Drummond et al”, International Journal of Technology Assessment in Health Care, Vol. 23 No. 3, pp. 397–404.
40. Milne, C.P. (2002), “Orphan products: pain relief for clinical development headaches”, Nature Biotechnology, Vol. 20 No. 8, pp. 780–4.
41. Novartis (2009), “Novartis annual report”, 2009, available at: http://ir2.flife.de/data/novartis2009/igb_html/index.php (accessed 18 August 2011).
42. Orofino, J., Soto, J., Casado, M.A. and Oyagüez, I. (2010), “Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007”, Applied Health Economics and Health Policy, Vol. 8 No. 5, pp. 301–15.
43. Parisse-Brassens, J. (2009), “Compassionate access to orphan drugs in the USA”, available at: www.eurordis.org/content/compassionate-access-orphan-drugs-us (accessed 18 August 2011).
44. Roos, J.C.P., Hyry, H.I. and Cox, T.M. (2010), “Orphan drug pricing may warrant a competition law investigation”, British Medical Journal, Vol. 341, November, pp. 1084–6.
45. Science and Technology Committee (2009), “Genomic medicine: volume 1”, available at: www.publications.parliament.uk/pa/ld200809/ldselect/ldsctech/107/10 7i.pdf (accessed 18 August 2011).
46. Stolk, P., Willemen, J.C. and Leufkens, H.G.M. (2006), “Rare essentials: drugs for rare diseases as essential medicines”, Bulletin - World Health Organization, Vol. 84 No. 9, pp. 745–51.
47. Stolk, P., Heemstra, H.E., Leufkens, H.G., Bloechl-Daum, B. and Heerdink, E.R. (2009), “No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products: a pilot study”, Orphanet Journal of Rare Diseases, Vol. 4 No. 1, p. 27.
48. Tejada, P. (2010), “Celebrating 10 years of the orphan drug regulation in Europe”, EURORDIS, available at: www.eurordis.org/content/celebrating-10-years-orphan-drug-regulation-europe (accessed 18 August 2011).
49. US Food and Drug Administration (2009), “Definition of disease prevalence”, available at: www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/DefinitionofDiseasePrevalence/default.htm (accessed 18 August 2011).
50. US Food and Drug Administration (2010a), “Developing products for rare diseases & conditions”, available at: www.fda.gov/forindustry/developingproductsforrarediseasesconditions/default.htm (accessed 18 August 2011).
51. US Food and Drug Administration (2010b), “Information on the orphan products grants program”, available at: www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/WhomtoContactaboutOrphanProductDevelopment/ucm134580 (accessed 18 August 2011).
52. US Food and Drug Administration (2011a), “FDA data search: orphan drug designations and approvals”, available at: www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm (accessed 18 August 2011).
53. US Food and Drug Administration (2011b), “Developing products for rare diseases & conditions”, available at: www.fda.gov/forindustry/developingproductsforrarediseasesconditions/default.htm (accessed 18 August 2011).
54. Vegter, S., Rozenbaum, M.H., Postema, R., Tolley, K. and Postma, M.J. (2010), “Review of regulatory recommendations for orphan drug submissions in The Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations”, Clinical Therapeutics, Vol. 32 No. 9, pp. 1651–61.
55. Villa, S., Compagni, A. and Reich, M.R. (2009), “Orphan drug legislation: lessons for neglected tropical diseases”, International Journal of Health Planning and Management, Vol. 24 No. 1, pp. 27–42.
56. Weinstein, M.C., Torrance, G. and McGuire, A. (2009), “QALYs: the basics”, Value in Health, Vol. 12, Supplement 1, pp. s5-s9.
57. Wästfelt, M., Fadeel, B. and Henter, J.I. (2006), “A journey of hope: lessons learned from studies on rare diseases and orphan drugs”, Journal of Internal Medicine, Vol. 260 No. 1, pp. 1–10.